Pulmonary embolism / VTE (acute)

pe-vte-acute

← back to Pulmonary & Critical Care

Summary

Second update to the 9th edition CHEST guideline on antithrombotic therapy for VTE, providing 29 guidance statements (13 strong) across 17 PICO questions covering initial management, treatment-phase anticoagulation, extended-phase secondary prevention, and PTS prevention. Major changes from 2016 include strong preference for DOACs over VKA for treatment phase, preference for oral Xa inhibitors over LMWH in cancer-associated thrombosis, new guidance on cerebral vein thrombosis, antiphospholipid syndrome, reduced-dose DOACs for extended phase, and superficial vein thrombosis. New nomenclature defines three phases: initiation (5-21 days), treatment (3 months), and extended (no preplanned stop date).

Current guideline: CHEST 2021 Antithrombotic Therapy for VTE · download Anki sub-deck

Versions

Table of contents